InsidersTradesSigma
Total declarations
Companies
▲ Purchases (46 ops.)
▼ Sales (85 ops.)
Insider track record
Board DirectorDisclosed buys
46
Disclosed sells
85
T+90 hit rate
47%
T+90 mean return
-8.2%
Across 15 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Orbimed Advisors Llc, Board Member. Director active across 46 companies, notably SpringWorks Therapeutics, Inc.. Cumulatively, 165 reports have been recorded. Breakdown: 46 buys · 85 sells. Total volume traded: €372.4m. History available since 7 June 2021. The latest transaction was filed on 10 August 2026 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Orbimed Advisors Llc
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations165 total
1,039,996 sharesCommon StockSEC:0000947871-26-000784:0
1,049,283 sharesCommon StockSEC:0000947871-26-000784:1
625,000 shares@ US$16.00Common StockSEC:0000947871-26-000784:2
Canonical exit: 8 Nov 2026 (T+90)
9,132,420 sharesCommon StockSEC:0000947871-26-000782:0
1,666,667 shares@ US$18.001.38% mcap85.9% of flowCommon StockSEC:0000947871-26-000782:1
Canonical exit: 5 Nov 2026 (T+90)
273,333 shares@ US$18.000.23% mcap14.1% of flowCommon StockSEC:0000947871-26-000782:2
Canonical exit: 5 Nov 2026 (T+90)
1,000,000 shares@ US$15.00100.0% of flowCommon StockSEC:0000947871-26-000733:1
Canonical exit: 25 Oct 2026 (T+90)
348,825 sharesCommon StockSEC:0000947871-26-000733:0
85,918 shares@ US$44.860.19% mcap13.5% of flowCommon StockSEC:0000947871-26-000694:0
24,846 sharesCommon StockSEC:0000947871-26-000653:0
1,477 sharesCommon StockSEC:0000947871-26-000653:1
46,776 sharesCommon StockSEC:0000947871-26-000653:3
787,024 sharesCommon StockSEC:0000947871-26-000653:2
597,729 shares@ US$1.674.37% mcap100.0% of flowCommon StockSEC:0000947871-26-000481:0
Canonical exit: 15 Jul 2026 (T+90)
1,689,189 shares@ US$4.441.84% mcap41.8% of flowCommon StockSEC:0000947871-26-000461:0
Canonical exit: 20 Jul 2026 (T+90)
1,126,126 shares@ US$4.441.23% mcap27.9% of flowCommon StockSEC:0000947871-26-000461:1
Canonical exit: 20 Jul 2026 (T+90)
52,397 shares@ US$44.680.11% mcap9.2% of flowCommon StockSEC:0000947871-26-000458:0
2,948 shares@ US$44.520.0063% mcap0.5% of flowCommon StockSEC:0000947871-26-000458:1
47,814 shares@ US$44.510.10% mcap8.4% of flowCommon StockSEC:0000947871-26-000446:0
235,863 shares@ US$44.640.50% mcap41.4% of flowCommon StockSEC:0000947871-26-000446:1
226,906 shares@ US$45.340.49% mcap40.5% of flowCommon StockSEC:0000947871-26-000446:2
29,319 shares@ US$6.531.6% of flowCommon StockSEC:0000947871-26-000421:0
2,400 shares@ US$6.380.1% of flowCommon StockSEC:0000947871-26-000421:1
32,523 shares@ US$6.291.7% of flowCommon StockSEC:0000947871-26-000421:2
40,416 shares@ US$6.522.2% of flowCommon StockSEC:0000947871-26-000421:3
25 of 165 declarations
About Orbimed Advisors Llc
ORBIMED ADVISORS LLC is a Board Member and has filed 157 disclosures in total. Across the 157 sampled recent filings, the reported amounts are EUR 95922088 in buys and EUR 305819195 in sells, with Cession shown as the modal transaction nature. Recent filings include activity in Sierra Oncology, Inc., Verona Pharma plc, Xtant Medical Holdings, Inc., Disc Medicine, Inc., Sionna Therapeutics, Inc. and Keros Therapeutics, Inc., over the period from 2021-06-09 to 2026-07-09.
